Estrella Immunopharma Advances STARLIGHT-1 Trial to Phase II
Estrella Immunopharma announced that an independent Data Safety Monitoring Board has completed its review of safety data from the Phase I dose escalation portion of the STARLIGHT-1 trial. Based on the safety profile observed, the DSMB recommended advancing the trial to Phase II, or the expansion phase, at the Recommended Phase II Dose. The expansion phase will further evaluate the safety and preliminary efficacy of EB103, the company's CD19-redirected Artemis T-cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin's lymphoma. In the Phase I dose escalation phase, no treatment-related serious adverse events were reported. The high-dose cohort achieved a 100% complete response rate at Month 1 in all evaluable patients.
Trade with 70% Backtested Accuracy
Analyst Views on ESLA
About ESLA
About the author
Estrella Immunopharma Closes $8 Million Financing to Advance Clinical Trials
- Successful Financing: Estrella Immunopharma has closed a registered direct offering with a single healthcare-focused institutional investor, issuing 4,063,290 shares of common stock and 1,000,000 pre-funded warrants, raising approximately $8 million, which enhances the company's financial resources for clinical development.
- Advancing Product Development: The proceeds will support the Phase II clinical trial of Estrella's lead product candidate, EB103, aimed at providing new treatment options for patients with cancers and autoimmune diseases who are not eligible for existing therapies, highlighting its significant clinical value.
- Investor Confidence: The CEO stated that this financing underscores continued investor support for the company's clinical vision, indicating strong market confidence in Estrella's future growth, which may facilitate further advancements in the biopharmaceutical sector.
- Compliance and Transparency: The financing adheres to SEC registration requirements, ensuring compliance in all securities transactions, while the company commits to filing registration statements with the SEC, thereby enhancing investor trust in the company's transparency.
Estrella Immunopharma Closes $8 Million Financing to Advance Clinical Trials
- Successful Financing: Estrella Immunopharma closed a registered direct offering with a single healthcare-focused institutional investor, raising approximately $8 million by issuing 4,063,290 shares of common stock and 1,000,000 pre-funded warrants, thereby strengthening its financial position to support clinical objectives.
- Advancing Clinical Programs: The financing will provide Estrella with the necessary resources to advance its lead product EB103 into Phase II clinical trials, aimed at offering treatment options for cancer patients who are ineligible for currently marketed therapies, which holds significant market potential.
- Investor Confidence: The CEO stated that this financing underscores continued investor support for the company's clinical vision, indicating market recognition of its ARTEMIS T-cell therapies, which may enhance future fundraising capabilities.
- Compliance Assurance: The offering was conducted under SEC registration statements, ensuring compliance, and through a registration rights agreement with the investor, Estrella will file registration statements to cover the resale of common stock, thereby boosting investor confidence.
D. Boral Capital Maintains Buy on Estrella Immunopharma, Maintains $16 Price Target
Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community Access: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma
Clinical Trial Expansion: Estrella Immunopharma has activated a second clinical site at Baylor Research Institute for its STARLIGHT-1 Phase I/II trial of EB103, a CD19-Redirected ARTEMIS® T-cell therapy aimed at treating relapsed or refractory B-cell non-Hodgkin's lymphoma.
Therapeutic Approach: EB103 utilizes innovative ARTEMIS® technology to target and destroy CD19-positive cancer cells, representing a potential advancement in safer and more effective treatments for patients with advanced NHL.
D. Boral Capital Maintains Buy on Estrella Immunopharma, Maintains $16 Price Target
Real-time Trading Intelligence: Benzinga Pro offers the fastest and most accurate stock market news alerts to help traders succeed in their investments.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and insights generated by Benzinga reporters.
D. Boral Capital Maintains Buy on Estrella Immunopharma, Maintains $16 Price Target
Real-time Trading Intelligence: Benzinga Pro offers the fastest and most accurate stock market news alerts to help traders succeed in their investments.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and insights generated by Benzinga reporters.
Estrella Immunopharma Closes $8 Million Financing to Advance Clinical Trials
- Successful Financing: Estrella Immunopharma has closed a registered direct offering with a single healthcare-focused institutional investor, issuing 4,063,290 shares of common stock and 1,000,000 pre-funded warrants, raising approximately $8 million, which enhances the company's financial resources for clinical development.
- Advancing Product Development: The proceeds will support the Phase II clinical trial of Estrella's lead product candidate, EB103, aimed at providing new treatment options for patients with cancers and autoimmune diseases who are not eligible for existing therapies, highlighting its significant clinical value.
- Investor Confidence: The CEO stated that this financing underscores continued investor support for the company's clinical vision, indicating strong market confidence in Estrella's future growth, which may facilitate further advancements in the biopharmaceutical sector.
- Compliance and Transparency: The financing adheres to SEC registration requirements, ensuring compliance in all securities transactions, while the company commits to filing registration statements with the SEC, thereby enhancing investor trust in the company's transparency.
Estrella Immunopharma Closes $8 Million Financing to Advance Clinical Trials
- Successful Financing: Estrella Immunopharma closed a registered direct offering with a single healthcare-focused institutional investor, raising approximately $8 million by issuing 4,063,290 shares of common stock and 1,000,000 pre-funded warrants, thereby strengthening its financial position to support clinical objectives.
- Advancing Clinical Programs: The financing will provide Estrella with the necessary resources to advance its lead product EB103 into Phase II clinical trials, aimed at offering treatment options for cancer patients who are ineligible for currently marketed therapies, which holds significant market potential.
- Investor Confidence: The CEO stated that this financing underscores continued investor support for the company's clinical vision, indicating market recognition of its ARTEMIS T-cell therapies, which may enhance future fundraising capabilities.
- Compliance Assurance: The offering was conducted under SEC registration statements, ensuring compliance, and through a registration rights agreement with the investor, Estrella will file registration statements to cover the resale of common stock, thereby boosting investor confidence.
D. Boral Capital Maintains Buy on Estrella Immunopharma, Maintains $16 Price Target
Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community Access: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma
Clinical Trial Expansion: Estrella Immunopharma has activated a second clinical site at Baylor Research Institute for its STARLIGHT-1 Phase I/II trial of EB103, a CD19-Redirected ARTEMIS® T-cell therapy aimed at treating relapsed or refractory B-cell non-Hodgkin's lymphoma.
Therapeutic Approach: EB103 utilizes innovative ARTEMIS® technology to target and destroy CD19-positive cancer cells, representing a potential advancement in safer and more effective treatments for patients with advanced NHL.
D. Boral Capital Maintains Buy on Estrella Immunopharma, Maintains $16 Price Target
Real-time Trading Intelligence: Benzinga Pro offers the fastest and most accurate stock market news alerts to help traders succeed in their investments.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and insights generated by Benzinga reporters.
D. Boral Capital Maintains Buy on Estrella Immunopharma, Maintains $16 Price Target
Real-time Trading Intelligence: Benzinga Pro offers the fastest and most accurate stock market news alerts to help traders succeed in their investments.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and insights generated by Benzinga reporters.
